Stellenwert der Induktionstherapie bei Kopf-Hals-Tumoren

Zusammenfassung

Nach den aktuellen Publikationen im New England Journal of Medicine (TAX323, TAX324) der Studiengruppen um Jan Vermorken und Marschall Posner scheint die Induktionschemotherapie bei Plattenepithelkarzinomen des Kopf-Hals-Bereichs (im Näheren: Oro-Hypopharynx, Mundhöhle und Larynx) derzeit weltweit eine Renaissance zu erfahren. Renaissance deshalb, weil in den letzten Jahrzehnten das Thema in dieser Gruppe von Tumoren nach ausbleibender Überlebensverbesserung in der überwiegenden Mehrzahl von Studien wieder verlassen worden war. Es stellt sich die Frage, welche Entitäten von der Induktion, derzeit als Kombination von Docetaxel, Cisplatin und 5-Fluorouracil (TPF) empfohlen, profitieren? Dem ungebrochen hohen Stellenwert der Chirurgie mit ergänzender Bestrahlung bzw. Radiochemotherapie stand bislang die primäre Radiochemotherapie bei nicht resektablen Tumoren gegenüber. Derzeitige Studienaktivitäten versuchen, die Rolle der Induktionschemotherapie im aktuellen multimodalen Kontext zu klären.

Abstract

According to recent publications in the New England Journal of Medicine (TAX323, TAX324) of the study groups around Jan Vermorken and Marshall Posner induction chemotherapy in squamous cell carcinomas of the head-neck area (in the closer: Oro-hypopharynx, oral cavity and larynx) currently seems to generate a worldwide renaissance. Renaissance, because in the last few decades, induction chemo therapy in this group of tumors after lack of survival improvement in the vast majority of studies was again abandoned. The new data raise the question for which entities induction chemo therapy can be recommended (actually, a combination of docetaxel, cisplatin and 5-fluorouracil; TPF)? The unbroken high value of primary surgery with adjuvant radiation or chemo radiation was complementary to primary radio chemotherapy for non resectable tumors until today worldwide. Running studies are sorting out the role of induction chemotherapy in the current context of clarifying optimal multimodal treatment.

Induktionschemotherapie - Kopf-Hals-Tumore - Kehlkopf-Organerhalt - Chemoselektion

induction chemotherapy - chemo selection - head and neck tumor - organ preservation

Literatur

• 1 Adelstein D, Saxton J, Lavertu P. et al . A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy aline in resectable stage III and IV squamous cell head and neck cancer: Preliminary results, chemoradiotherapy vs. radiotherapy.  Head Neck. 1997;  19 567-575
• 2 Adelstein D, Li Y, Adams G. et al . An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.  J Clin Oncol. 2003;  21 92-98
• 3 Bernier J, Schneider D. Cetuximab combined with radiotherapy: An alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck?.  Eur J Cancer. 2007;  43 35-45
• 4 Bonnano P C. Swallowing dysfunction after tracheotomy.  Ann Surg. 1971;  174 29-33
• 5 Bonner J A, Harari P M, Giralt J, Azarnia N, Shin D M, Cohen R B, Jones C U, Sur R, Raben D, Jassem J, Ove R, Kies M S, Baselga J, Youssoufian H, Amellal N, Rowinsky E K, Ang K K. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.  N Engl J Med. 2006;  354 567-578
• 6 Bourhis J, Overgaard J, Audry H, Ang K K, Saunders M, Bernier J, Horiot J C, Le Maitre A, Pajak T F, Poulsen M G, O’Sullivan B, Dobrowsky W, Hliniak A, Skladowski K, Hay J H, Pinto L H, Fallai C, Fu K K, Sylvester R, Pignon J P.. Meta-Analysis of Radiotherapy in Carcinomas of Head and neck (MARCH) Collaborative Group . Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis.  Lancet. 2006;  368 843-854
• 7 Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Oudinot P, Bertrand P. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma.  J Natl Cancer Inst. 1999;  91 2081-2086
• 8 Calais G, Pointreau Y, Alfonsi M, Sire C, Tuchais C, Tortochaux J, Bourhis J, Guerrif S, Garaud P. 2006 ASCO Annual Meeting Proceedings Part I.  Journal of Clinical Oncology. 2006;  Vol 24 No. 18 S (June 20 Supplement) 5506
• 9 Cox J D, Stetz J, Pajak T. et al . Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC).  Int J Radiat Oncol Biol Phys. 1995;  31 1341-1346
• 10 Denis F, Garaud P, Bardet E. et al . Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced stage oropharynx carcinoma: Comparison of the LENT/SOMA, RTOG/EORTC, and the NCI-CTC scoring systems.  Int J Radiat Oncol Biol Phys. 2003;  55 93-98
• 11 Dietz A, Nollert J, Eckel H, Volling P, Schroder M, Staar S, Conradt C, Helmke B, Dollner R, Muller R P, Wannenmacher M, Weidauer H, Rudat V. Organerhalt beim fortgeschrittenen Larynx- bzw. Hypopharynxkarzinom durch primäre Radiochemotherapie.  HNO. 2002;  50 146-154
• 12 Dietz A, Rudat V, Nollert J, Helbig M, Vanselow B, Weidauer H. Chronic laryngeal edema as a late reaction to radiochemotherapy.  HNO. 1998;  46 731-738
• 13 Dietz A, Rudat V, Hoppe F, Pfreundner L, Flentje M. Induction chemotherapy with paclitaxel and cisplatin, followed by accelerated-hyperfractionated radiotherapy in patients with advanced laryngeal and hypopharyngeal cancer - the DeLOS (Deutsche Larynxorganerhaltung-Studiengruppe)-trial Procedings. Berlin; Deutscher Krebskongress 2006
• 14 Dische S, Warburton M, Jones D. et al . The recording of morbidity related to radiotherapy.  Radiat Oncol. 1989;  16 103-108
• 15 Eibling D E, Gross R D. Subglottic air pressure: a key component of swallowing efficiency.  Ann Otol Rhinol Laryngol. 1996;  105 253-258
• 16 Feldmann S A, Deal C W, Urquhart W. Disturbance of swallowing after tracheotomy.  Lancet. 1966;  1 954-955
• 17 Forastiere A A, Goepfert H, Maor M, Pajak T F, Weber R, Morrison W, Glisson B, Trotti A, Ridge J A, Chao C, Peters G, Lee D J, Leaf A, Ensley J, Cooper J. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.  N Engl J Med. 2003;  349 2091-2098
• 18 Forastiere A A, Maor M, Weber R S. et al . Long-term results of Intergroup RTOG 91-11: A phase III trial to preserve the larynx-Induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. 2006 ASCO Annual Meeting Proceedings Part I.  Journal of Clinical Oncology. 2006;  24 5517
• 19 Higgins D M, Maclean J C. Dysphagia in the patient with a tracheostomy: Six cases of inappropriate cuff deflation or removal.  Heart and Lung. 1997;  26 215-220
• 20 Hillman R E, Walsh M J, Wolf G T, Fisher S G, Hong W K. Functional outcomes following treatment for advanced laryngeal cancer. Part I - Voice preservation in advanced laryngeal cancer. Part II - Laryngectomy rehabilitation: the state of the art in the VA System. Research Speech-Language Pathologists. Department of Veterans Affairs Laryngeal Cancer Study Group.  Ann Otol Rhinol Laryngol. 1998;  Suppl 172 1-27
• 21 Hitt R, Lopez-Pousa A, Martinez-Trufero J, Escrig V, Carles J, Rizo A, Isla D, Vega M E, Marti J L, Lobo F, Pastor P, Valenti V, Belon J, Sanchez M A, Chaib C, Pallares C, Anton A, Cervantes A, Paz-Ares L, Cortes-Funes H. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.  J Clin Oncol. 2005;  23 8636-8645
• 22 Hoffman H T, Porter K, Karnell L H, Cooper J S, Weber R S, Langer C J, Ang K K, Gay G, Stewart A, Robinson R A. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival.  Laryngoscope. 2006;  116 1529-1542
• 23 Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A, Aleksandrovic J, Vaskovic Z, Tadic L. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial.  J Clin Oncol. 2000;  18 1458-1464
• 24 Knecht R, Baghi M, Hambek M, Tesch H, Gstottner W. Response rate and outcome of a novel induction chemotherapy regimen (TPF) in the first-line therapy of advanced head and neck carcinomas (SCCHN).  Proc Am Soc Clin Oncol. 2003;  22 501 (Abstract 2017)
• 25 Lefebvre J L, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group.  J Natl Cancer Inst. 1996;  88 890-899
• 26 Mohide E A, Archibald S D, Tew M, Young J E, Haines T. Postlaryngectomy quality-of-life dimensions identified by patients and health care professionals.  Am J Surg. 1992;  164 619-622
• 27 Murray J. The laryngoscopic evaluation of swallowing or fees.  In: Murray J (ed). Manual of Dysphagia Assessment in Adults. Singular Publishing Group, Inc 1999: 153-190
• 28 Nash M. Swallowing problems in tracheotomized patient.  Otolaryngol Clin North Am. 1988;  21 701-709
• 29 NCI/CTC Web site .http://ctep.info.nih.gov
• 30 Pfreundner L, Hoppe F, Willner J, Preisler V, Bratengeier K, Hagen R, Helms J, Flentje M. Induction chemotherapy with paclitaxel and cisplatin and CT-based 3D radiotherapy in patients with advanced laryngeal and hypopharyngeal carcinomas - a possibility for organ preservation.  Radiother Oncol. 2003;  68 163-170
• 31 Pignon J P, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.  Lancet. 2000;  355 949-955
• 32 Posner M R, Hershock D M, Blajman C R, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin D M, Cullen K, Ervin T J, Murphy B A, Raez L E, Cohen R B, Spaulding M, Tishler R B, Roth B, Viroglio, Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter K W, Dugan M, Cmelak A, Markoe A M, Read P W, Steinbrenner L, Colevas A D, Norris Jr C M, Haddad R I.. TAX 324 Study Group . Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.  N Engl J Med. 2007;  357 1705-1715
• 33 Richard J M, Sancho-Garnier H, Pessey J J, Luboinski B, Lefebvre J L, Dehesdin D, Stromboni-Luboinski M, Hill C. Randomized trial of induction chemotherapy in larynx carcinoma.  Oral Oncol. 1998;  34 224-228
• 34 Rosenthal D I, Lewin J S, Eisbruch A. Dysphagia after radiation therapy or chemoradiation for head and neck cancer.  J Clin Oncol. 2006;  24 2636-2643
• 35 Rubin P, Constine S, Fajardo L. et al . Overview of late effects of normal tissues (LENT-SOMA) scoring system.  Int J Radiat Oncol Biol Phys. 1995;  31 1041-1042
• 36 Shaker R, Milbarth M, Ren J, Campbell B, Toohill R, Hogan W. Deglutitive Aspiration with tracheostomy: Effect of Tracheostomy on the duration of vocal chord closure.  Gastroenterology. 1995;  108 154-159
• 37 Simon C, Plinkert P K. Transoral resection of locally advanced squamous cell carcinoma of the side wall of the oropharynx: multimodal treatment concepts in transition.  Laryngoscope. 2006;  116 1529
• 38 Sticher H, Gratz C. Trachealkanülen-Management in der F. O. T. T. - Der Weg zurück zur Physiologie.  In: Nusser-Müller-Busch R (Hrsg). Die Therapie des Facio-Oralen Trakts. Berlin, Heidelberg; Springer 2004: 181-190
• 39 Terrell J E, Fisher S G, Wolf G T. Long-term quality of life after treatment of laryngeal cancer. The Veterans Affairs Laryngeal Cancer Study Group.  Arch Otolaryngol Head Neck Surg. 1998;  124 964-971
• 40 The Department of Veterans Affairs Laryngeal Cancer Study Group . Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.  N Engl J Med. 1991;  324 1685-1690
• 41 Tolep K, Getch C L, Criner G J. Swallowing dysfunction in patients receiving prolonged mechanical ventilation.  Chest. 1996;  109 167-172
• 42 Trotti A, Bentzen S M. The need for adverse effects reporting standards in oncology clinical trials.  J Clin Oncol. 2004;  22 19-22
• 43 Vermorken J B, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart J S, Jelic S, Betka J, Preiss J H, van den Weyngaert D, Awada A, Cupissol D, Kienzer H R, Rey A, Desaunois I, Bernier J, Lefebvre J L.. EORTC 24 971/TAX 323 Study Group . Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.  N Engl J Med. 2007;  357 1695-1704
• 44 Waters T, Logemann J, Pauloski B. et al . Beyond efficacy and effectiveness: Conducting economic analyses during clinical trials.  Dysphagia. 2004;  19 109-119
• 45 World Health Organization .WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland; WHO Offset publication No. 48 1979
• 46 Wyke B D. Myotactic reflexogenic systems in the larynx.  Folia morphologica (Praha). 1973;  21 113-117